Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ortec International

This article was originally published in The Gray Sheet

Executive Summary

Initiates 120-patient, six-center trial of its Composite Cultured Skin for the treatment of "full and deep partial thickness burns," with the first patient enrolled March 16 at the Cornell New York Hospital Burn Center, New York City. The Composite Cultured Skin is "a biologically active dressing composed of a biodegradable matrix seeded with epidermal and dermal cells derived from infant foreskins" and "induces the rapid regeneration of healthy skin with minimal scarring and without the need for autografts," according to the Glendale, New York-based private firm
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT002081

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel